Document Detail


How do we improve patient compliance and adherence to long-term statin therapy?
MedLine Citation:
PMID:  23225173     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Statins are highly effective drugs prescribed to millions of people to lower LDL-cholesterol and decrease cardiovascular risk. The benefits of statin therapy seen in randomized clinical trials will only be replicated in real-life if patients adhere to the prescribed treatment regimen. But, about half of patients discontinue statin therapy within the first year, and adherence decreases with time. Patient, physician and healthcare system-related factors play a role in this problem. Recent studies have focused more on the patients' perspectives on non-adherence. Adverse events are cited as the most common cause of statin discontinuation; thus, the healthcare provider must be willing to ally and dialogue with patients to address concerns and assess the risks and benefits of continued statin therapy.
Authors:
Patricia Maningat; Bruce R Gordon; Jan L Breslow
Related Documents :
22963213 - Direct and delayed admission to an intensive care or high dependency unit following dis...
23372343 - Imatinib as preoperative therapy in chinese patients with recurrent or metastatic gists.
24151363 - Emergency admissions due to swallowed foreign bodies in adults.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  15     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-10     Completed Date:  2013-05-21     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  291     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases / blood,  prevention & control*
Cholesterol, LDL / blood,  drug effects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / blood,  therapeutic use*
Patient Compliance*
Primary Prevention / methods*
Time Factors
Grant Support
ID/Acronym/Agency:
UL1 TR000043/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Screening for bacteremia in sepsis and renal failure using hemofilters for renal replacement therapy...
Next Document:  Lipid effects of psychiatric medications.